1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Carcinoid Tumor Syndrome Treatment Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Carcinoid Tumor Syndrome Treatment by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Carcinoid Tumor Syndrome Treatment by Country/Region, 2018, 2022 & 2029
2.2 Carcinoid Tumor Syndrome Treatment Segment by Type
2.2.1 Chemotherapy
2.2.2 Biological Therapy
2.2.3 Radio Therapy
2.3 Carcinoid Tumor Syndrome Treatment Sales by Type
2.3.1 Global Carcinoid Tumor Syndrome Treatment Sales Market Share by Type (2018-2023)
2.3.2 Global Carcinoid Tumor Syndrome Treatment Revenue and Market Share by Type (2018-2023)
2.3.3 Global Carcinoid Tumor Syndrome Treatment Sale Price by Type (2018-2023)
2.4 Carcinoid Tumor Syndrome Treatment Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Home
2.5 Carcinoid Tumor Syndrome Treatment Sales by Application
2.5.1 Global Carcinoid Tumor Syndrome Treatment Sale Market Share by Application (2018-2023)
2.5.2 Global Carcinoid Tumor Syndrome Treatment Revenue and Market Share by Application (2018-2023)
2.5.3 Global Carcinoid Tumor Syndrome Treatment Sale Price by Application (2018-2023)
3 Global Carcinoid Tumor Syndrome Treatment by Company
3.1 Global Carcinoid Tumor Syndrome Treatment Breakdown Data by Company
3.1.1 Global Carcinoid Tumor Syndrome Treatment Annual Sales by Company (2018-2023)
3.1.2 Global Carcinoid Tumor Syndrome Treatment Sales Market Share by Company (2018-2023)
3.2 Global Carcinoid Tumor Syndrome Treatment Annual Revenue by Company (2018-2023)
3.2.1 Global Carcinoid Tumor Syndrome Treatment Revenue by Company (2018-2023)
3.2.2 Global Carcinoid Tumor Syndrome Treatment Revenue Market Share by Company (2018-2023)
3.3 Global Carcinoid Tumor Syndrome Treatment Sale Price by Company
3.4 Key Manufacturers Carcinoid Tumor Syndrome Treatment Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Carcinoid Tumor Syndrome Treatment Product Location Distribution
3.4.2 Players Carcinoid Tumor Syndrome Treatment Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Carcinoid Tumor Syndrome Treatment by Geographic Region
4.1 World Historic Carcinoid Tumor Syndrome Treatment Market Size by Geographic Region (2018-2023)
4.1.1 Global Carcinoid Tumor Syndrome Treatment Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Carcinoid Tumor Syndrome Treatment Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Carcinoid Tumor Syndrome Treatment Market Size by Country/Region (2018-2023)
4.2.1 Global Carcinoid Tumor Syndrome Treatment Annual Sales by Country/Region (2018-2023)
4.2.2 Global Carcinoid Tumor Syndrome Treatment Annual Revenue by Country/Region (2018-2023)
4.3 Americas Carcinoid Tumor Syndrome Treatment Sales Growth
4.4 APAC Carcinoid Tumor Syndrome Treatment Sales Growth
4.5 Europe Carcinoid Tumor Syndrome Treatment Sales Growth
4.6 Middle East & Africa Carcinoid Tumor Syndrome Treatment Sales Growth
5 Americas
5.1 Americas Carcinoid Tumor Syndrome Treatment Sales by Country
5.1.1 Americas Carcinoid Tumor Syndrome Treatment Sales by Country (2018-2023)
5.1.2 Americas Carcinoid Tumor Syndrome Treatment Revenue by Country (2018-2023)
5.2 Americas Carcinoid Tumor Syndrome Treatment Sales by Type
5.3 Americas Carcinoid Tumor Syndrome Treatment Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Carcinoid Tumor Syndrome Treatment Sales by Region
6.1.1 APAC Carcinoid Tumor Syndrome Treatment Sales by Region (2018-2023)
6.1.2 APAC Carcinoid Tumor Syndrome Treatment Revenue by Region (2018-2023)
6.2 APAC Carcinoid Tumor Syndrome Treatment Sales by Type
6.3 APAC Carcinoid Tumor Syndrome Treatment Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Carcinoid Tumor Syndrome Treatment by Country
7.1.1 Europe Carcinoid Tumor Syndrome Treatment Sales by Country (2018-2023)
7.1.2 Europe Carcinoid Tumor Syndrome Treatment Revenue by Country (2018-2023)
7.2 Europe Carcinoid Tumor Syndrome Treatment Sales by Type
7.3 Europe Carcinoid Tumor Syndrome Treatment Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Carcinoid Tumor Syndrome Treatment by Country
8.1.1 Middle East & Africa Carcinoid Tumor Syndrome Treatment Sales by Country (2018-2023)
8.1.2 Middle East & Africa Carcinoid Tumor Syndrome Treatment Revenue by Country (2018-2023)
8.2 Middle East & Africa Carcinoid Tumor Syndrome Treatment Sales by Type
8.3 Middle East & Africa Carcinoid Tumor Syndrome Treatment Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Carcinoid Tumor Syndrome Treatment
10.3 Manufacturing Process Analysis of Carcinoid Tumor Syndrome Treatment
10.4 Industry Chain Structure of Carcinoid Tumor Syndrome Treatment
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Carcinoid Tumor Syndrome Treatment Distributors
11.3 Carcinoid Tumor Syndrome Treatment Customer
12 World Forecast Review for Carcinoid Tumor Syndrome Treatment by Geographic Region
12.1 Global Carcinoid Tumor Syndrome Treatment Market Size Forecast by Region
12.1.1 Global Carcinoid Tumor Syndrome Treatment Forecast by Region (2024-2029)
12.1.2 Global Carcinoid Tumor Syndrome Treatment Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Carcinoid Tumor Syndrome Treatment Forecast by Type
12.7 Global Carcinoid Tumor Syndrome Treatment Forecast by Application
13 Key Players Analysis
13.1 Novartis AG
13.1.1 Novartis AG Company Information
13.1.2 Novartis AG Carcinoid Tumor Syndrome Treatment Product Portfolios and Specifications
13.1.3 Novartis AG Carcinoid Tumor Syndrome Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Novartis AG Main Business Overview
13.1.5 Novartis AG Latest Developments
13.2 Teva Pharmaceutical Industries Ltd.
13.2.1 Teva Pharmaceutical Industries Ltd. Company Information
13.2.2 Teva Pharmaceutical Industries Ltd. Carcinoid Tumor Syndrome Treatment Product Portfolios and Specifications
13.2.3 Teva Pharmaceutical Industries Ltd. Carcinoid Tumor Syndrome Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Teva Pharmaceutical Industries Ltd. Main Business Overview
13.2.5 Teva Pharmaceutical Industries Ltd. Latest Developments
13.3 Mylan N.V.
13.3.1 Mylan N.V. Company Information
13.3.2 Mylan N.V. Carcinoid Tumor Syndrome Treatment Product Portfolios and Specifications
13.3.3 Mylan N.V. Carcinoid Tumor Syndrome Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Mylan N.V. Main Business Overview
13.3.5 Mylan N.V. Latest Developments
13.4 Ipsen Biopharmaceuticals, Inc
13.4.1 Ipsen Biopharmaceuticals, Inc Company Information
13.4.2 Ipsen Biopharmaceuticals, Inc Carcinoid Tumor Syndrome Treatment Product Portfolios and Specifications
13.4.3 Ipsen Biopharmaceuticals, Inc Carcinoid Tumor Syndrome Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Ipsen Biopharmaceuticals, Inc Main Business Overview
13.4.5 Ipsen Biopharmaceuticals, Inc Latest Developments
13.5 Sun Pharmaceutical Industries Ltd
13.5.1 Sun Pharmaceutical Industries Ltd Company Information
13.5.2 Sun Pharmaceutical Industries Ltd Carcinoid Tumor Syndrome Treatment Product Portfolios and Specifications
13.5.3 Sun Pharmaceutical Industries Ltd Carcinoid Tumor Syndrome Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Sun Pharmaceutical Industries Ltd Main Business Overview
13.5.5 Sun Pharmaceutical Industries Ltd Latest Developments
13.6 Amgen Inc.
13.6.1 Amgen Inc. Company Information
13.6.2 Amgen Inc. Carcinoid Tumor Syndrome Treatment Product Portfolios and Specifications
13.6.3 Amgen Inc. Carcinoid Tumor Syndrome Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Amgen Inc. Main Business Overview
13.6.5 Amgen Inc. Latest Developments
13.7 Entrinsic Health Solutions, Inc.
13.7.1 Entrinsic Health Solutions, Inc. Company Information
13.7.2 Entrinsic Health Solutions, Inc. Carcinoid Tumor Syndrome Treatment Product Portfolios and Specifications
13.7.3 Entrinsic Health Solutions, Inc. Carcinoid Tumor Syndrome Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Entrinsic Health Solutions, Inc. Main Business Overview
13.7.5 Entrinsic Health Solutions, Inc. Latest Developments
13.8 Endo Pharmaceuticals Inc.
13.8.1 Endo Pharmaceuticals Inc. Company Information
13.8.2 Endo Pharmaceuticals Inc. Carcinoid Tumor Syndrome Treatment Product Portfolios and Specifications
13.8.3 Endo Pharmaceuticals Inc. Carcinoid Tumor Syndrome Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Endo Pharmaceuticals Inc. Main Business Overview
13.8.5 Endo Pharmaceuticals Inc. Latest Developments
13.9 Sirtex SIR-Spheres Pty Ltd
13.9.1 Sirtex SIR-Spheres Pty Ltd Company Information
13.9.2 Sirtex SIR-Spheres Pty Ltd Carcinoid Tumor Syndrome Treatment Product Portfolios and Specifications
13.9.3 Sirtex SIR-Spheres Pty Ltd Carcinoid Tumor Syndrome Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Sirtex SIR-Spheres Pty Ltd Main Business Overview
13.9.5 Sirtex SIR-Spheres Pty Ltd Latest Developments
13.10 BTG International Ltd
13.10.1 BTG International Ltd Company Information
13.10.2 BTG International Ltd Carcinoid Tumor Syndrome Treatment Product Portfolios and Specifications
13.10.3 BTG International Ltd Carcinoid Tumor Syndrome Treatment Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 BTG International Ltd Main Business Overview
13.10.5 BTG International Ltd Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. Carcinoid Tumor Syndrome Treatment Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Carcinoid Tumor Syndrome Treatment Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Chemotherapy
Table 4. Major Players of Biological Therapy
Table 5. Major Players of Radio Therapy
Table 6. Global Carcinoid Tumor Syndrome Treatment Sales by Type (2018-2023) & (K Units)
Table 7. Global Carcinoid Tumor Syndrome Treatment Sales Market Share by Type (2018-2023)
Table 8. Global Carcinoid Tumor Syndrome Treatment Revenue by Type (2018-2023) & ($ million)
Table 9. Global Carcinoid Tumor Syndrome Treatment Revenue Market Share by Type (2018-2023)
Table 10. Global Carcinoid Tumor Syndrome Treatment Sale Price by Type (2018-2023) & (US$/Unit)
Table 11. Global Carcinoid Tumor Syndrome Treatment Sales by Application (2018-2023) & (K Units)
Table 12. Global Carcinoid Tumor Syndrome Treatment Sales Market Share by Application (2018-2023)
Table 13. Global Carcinoid Tumor Syndrome Treatment Revenue by Application (2018-2023)
Table 14. Global Carcinoid Tumor Syndrome Treatment Revenue Market Share by Application (2018-2023)
Table 15. Global Carcinoid Tumor Syndrome Treatment Sale Price by Application (2018-2023) & (US$/Unit)
Table 16. Global Carcinoid Tumor Syndrome Treatment Sales by Company (2018-2023) & (K Units)
Table 17. Global Carcinoid Tumor Syndrome Treatment Sales Market Share by Company (2018-2023)
Table 18. Global Carcinoid Tumor Syndrome Treatment Revenue by Company (2018-2023) ($ Millions)
Table 19. Global Carcinoid Tumor Syndrome Treatment Revenue Market Share by Company (2018-2023)
Table 20. Global Carcinoid Tumor Syndrome Treatment Sale Price by Company (2018-2023) & (US$/Unit)
Table 21. Key Manufacturers Carcinoid Tumor Syndrome Treatment Producing Area Distribution and Sales Area
Table 22. Players Carcinoid Tumor Syndrome Treatment Products Offered
Table 23. Carcinoid Tumor Syndrome Treatment Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Carcinoid Tumor Syndrome Treatment Sales by Geographic Region (2018-2023) & (K Units)
Table 27. Global Carcinoid Tumor Syndrome Treatment Sales Market Share Geographic Region (2018-2023)
Table 28. Global Carcinoid Tumor Syndrome Treatment Revenue by Geographic Region (2018-2023) & ($ millions)
Table 29. Global Carcinoid Tumor Syndrome Treatment Revenue Market Share by Geographic Region (2018-2023)
Table 30. Global Carcinoid Tumor Syndrome Treatment Sales by Country/Region (2018-2023) & (K Units)
Table 31. Global Carcinoid Tumor Syndrome Treatment Sales Market Share by Country/Region (2018-2023)
Table 32. Global Carcinoid Tumor Syndrome Treatment Revenue by Country/Region (2018-2023) & ($ millions)
Table 33. Global Carcinoid Tumor Syndrome Treatment Revenue Market Share by Country/Region (2018-2023)
Table 34. Americas Carcinoid Tumor Syndrome Treatment Sales by Country (2018-2023) & (K Units)
Table 35. Americas Carcinoid Tumor Syndrome Treatment Sales Market Share by Country (2018-2023)
Table 36. Americas Carcinoid Tumor Syndrome Treatment Revenue by Country (2018-2023) & ($ Millions)
Table 37. Americas Carcinoid Tumor Syndrome Treatment Revenue Market Share by Country (2018-2023)
Table 38. Americas Carcinoid Tumor Syndrome Treatment Sales by Type (2018-2023) & (K Units)
Table 39. Americas Carcinoid Tumor Syndrome Treatment Sales by Application (2018-2023) & (K Units)
Table 40. APAC Carcinoid Tumor Syndrome Treatment Sales by Region (2018-2023) & (K Units)
Table 41. APAC Carcinoid Tumor Syndrome Treatment Sales Market Share by Region (2018-2023)
Table 42. APAC Carcinoid Tumor Syndrome Treatment Revenue by Region (2018-2023) & ($ Millions)
Table 43. APAC Carcinoid Tumor Syndrome Treatment Revenue Market Share by Region (2018-2023)
Table 44. APAC Carcinoid Tumor Syndrome Treatment Sales by Type (2018-2023) & (K Units)
Table 45. APAC Carcinoid Tumor Syndrome Treatment Sales by Application (2018-2023) & (K Units)
Table 46. Europe Carcinoid Tumor Syndrome Treatment Sales by Country (2018-2023) & (K Units)
Table 47. Europe Carcinoid Tumor Syndrome Treatment Sales Market Share by Country (2018-2023)
Table 48. Europe Carcinoid Tumor Syndrome Treatment Revenue by Country (2018-2023) & ($ Millions)
Table 49. Europe Carcinoid Tumor Syndrome Treatment Revenue Market Share by Country (2018-2023)
Table 50. Europe Carcinoid Tumor Syndrome Treatment Sales by Type (2018-2023) & (K Units)
Table 51. Europe Carcinoid Tumor Syndrome Treatment Sales by Application (2018-2023) & (K Units)
Table 52. Middle East & Africa Carcinoid Tumor Syndrome Treatment Sales by Country (2018-2023) & (K Units)
Table 53. Middle East & Africa Carcinoid Tumor Syndrome Treatment Sales Market Share by Country (2018-2023)
Table 54. Middle East & Africa Carcinoid Tumor Syndrome Treatment Revenue by Country (2018-2023) & ($ Millions)
Table 55. Middle East & Africa Carcinoid Tumor Syndrome Treatment Revenue Market Share by Country (2018-2023)
Table 56. Middle East & Africa Carcinoid Tumor Syndrome Treatment Sales by Type (2018-2023) & (K Units)
Table 57. Middle East & Africa Carcinoid Tumor Syndrome Treatment Sales by Application (2018-2023) & (K Units)
Table 58. Key Market Drivers & Growth Opportunities of Carcinoid Tumor Syndrome Treatment
Table 59. Key Market Challenges & Risks of Carcinoid Tumor Syndrome Treatment
Table 60. Key Industry Trends of Carcinoid Tumor Syndrome Treatment
Table 61. Carcinoid Tumor Syndrome Treatment Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. Carcinoid Tumor Syndrome Treatment Distributors List
Table 64. Carcinoid Tumor Syndrome Treatment Customer List
Table 65. Global Carcinoid Tumor Syndrome Treatment Sales Forecast by Region (2024-2029) & (K Units)
Table 66. Global Carcinoid Tumor Syndrome Treatment Revenue Forecast by Region (2024-2029) & ($ millions)
Table 67. Americas Carcinoid Tumor Syndrome Treatment Sales Forecast by Country (2024-2029) & (K Units)
Table 68. Americas Carcinoid Tumor Syndrome Treatment Revenue Forecast by Country (2024-2029) & ($ millions)
Table 69. APAC Carcinoid Tumor Syndrome Treatment Sales Forecast by Region (2024-2029) & (K Units)
Table 70. APAC Carcinoid Tumor Syndrome Treatment Revenue Forecast by Region (2024-2029) & ($ millions)
Table 71. Europe Carcinoid Tumor Syndrome Treatment Sales Forecast by Country (2024-2029) & (K Units)
Table 72. Europe Carcinoid Tumor Syndrome Treatment Revenue Forecast by Country (2024-2029) & ($ millions)
Table 73. Middle East & Africa Carcinoid Tumor Syndrome Treatment Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Middle East & Africa Carcinoid Tumor Syndrome Treatment Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Global Carcinoid Tumor Syndrome Treatment Sales Forecast by Type (2024-2029) & (K Units)
Table 76. Global Carcinoid Tumor Syndrome Treatment Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 77. Global Carcinoid Tumor Syndrome Treatment Sales Forecast by Application (2024-2029) & (K Units)
Table 78. Global Carcinoid Tumor Syndrome Treatment Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 79. Novartis AG Basic Information, Carcinoid Tumor Syndrome Treatment Manufacturing Base, Sales Area and Its Competitors
Table 80. Novartis AG Carcinoid Tumor Syndrome Treatment Product Portfolios and Specifications
Table 81. Novartis AG Carcinoid Tumor Syndrome Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 82. Novartis AG Main Business
Table 83. Novartis AG Latest Developments
Table 84. Teva Pharmaceutical Industries Ltd. Basic Information, Carcinoid Tumor Syndrome Treatment Manufacturing Base, Sales Area and Its Competitors
Table 85. Teva Pharmaceutical Industries Ltd. Carcinoid Tumor Syndrome Treatment Product Portfolios and Specifications
Table 86. Teva Pharmaceutical Industries Ltd. Carcinoid Tumor Syndrome Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 87. Teva Pharmaceutical Industries Ltd. Main Business
Table 88. Teva Pharmaceutical Industries Ltd. Latest Developments
Table 89. Mylan N.V. Basic Information, Carcinoid Tumor Syndrome Treatment Manufacturing Base, Sales Area and Its Competitors
Table 90. Mylan N.V. Carcinoid Tumor Syndrome Treatment Product Portfolios and Specifications
Table 91. Mylan N.V. Carcinoid Tumor Syndrome Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 92. Mylan N.V. Main Business
Table 93. Mylan N.V. Latest Developments
Table 94. Ipsen Biopharmaceuticals, Inc Basic Information, Carcinoid Tumor Syndrome Treatment Manufacturing Base, Sales Area and Its Competitors
Table 95. Ipsen Biopharmaceuticals, Inc Carcinoid Tumor Syndrome Treatment Product Portfolios and Specifications
Table 96. Ipsen Biopharmaceuticals, Inc Carcinoid Tumor Syndrome Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 97. Ipsen Biopharmaceuticals, Inc Main Business
Table 98. Ipsen Biopharmaceuticals, Inc Latest Developments
Table 99. Sun Pharmaceutical Industries Ltd Basic Information, Carcinoid Tumor Syndrome Treatment Manufacturing Base, Sales Area and Its Competitors
Table 100. Sun Pharmaceutical Industries Ltd Carcinoid Tumor Syndrome Treatment Product Portfolios and Specifications
Table 101. Sun Pharmaceutical Industries Ltd Carcinoid Tumor Syndrome Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 102. Sun Pharmaceutical Industries Ltd Main Business
Table 103. Sun Pharmaceutical Industries Ltd Latest Developments
Table 104. Amgen Inc. Basic Information, Carcinoid Tumor Syndrome Treatment Manufacturing Base, Sales Area and Its Competitors
Table 105. Amgen Inc. Carcinoid Tumor Syndrome Treatment Product Portfolios and Specifications
Table 106. Amgen Inc. Carcinoid Tumor Syndrome Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 107. Amgen Inc. Main Business
Table 108. Amgen Inc. Latest Developments
Table 109. Entrinsic Health Solutions, Inc. Basic Information, Carcinoid Tumor Syndrome Treatment Manufacturing Base, Sales Area and Its Competitors
Table 110. Entrinsic Health Solutions, Inc. Carcinoid Tumor Syndrome Treatment Product Portfolios and Specifications
Table 111. Entrinsic Health Solutions, Inc. Carcinoid Tumor Syndrome Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 112. Entrinsic Health Solutions, Inc. Main Business
Table 113. Entrinsic Health Solutions, Inc. Latest Developments
Table 114. Endo Pharmaceuticals Inc. Basic Information, Carcinoid Tumor Syndrome Treatment Manufacturing Base, Sales Area and Its Competitors
Table 115. Endo Pharmaceuticals Inc. Carcinoid Tumor Syndrome Treatment Product Portfolios and Specifications
Table 116. Endo Pharmaceuticals Inc. Carcinoid Tumor Syndrome Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 117. Endo Pharmaceuticals Inc. Main Business
Table 118. Endo Pharmaceuticals Inc. Latest Developments
Table 119. Sirtex SIR-Spheres Pty Ltd Basic Information, Carcinoid Tumor Syndrome Treatment Manufacturing Base, Sales Area and Its Competitors
Table 120. Sirtex SIR-Spheres Pty Ltd Carcinoid Tumor Syndrome Treatment Product Portfolios and Specifications
Table 121. Sirtex SIR-Spheres Pty Ltd Carcinoid Tumor Syndrome Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 122. Sirtex SIR-Spheres Pty Ltd Main Business
Table 123. Sirtex SIR-Spheres Pty Ltd Latest Developments
Table 124. BTG International Ltd Basic Information, Carcinoid Tumor Syndrome Treatment Manufacturing Base, Sales Area and Its Competitors
Table 125. BTG International Ltd Carcinoid Tumor Syndrome Treatment Product Portfolios and Specifications
Table 126. BTG International Ltd Carcinoid Tumor Syndrome Treatment Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 127. BTG International Ltd Main Business
Table 128. BTG International Ltd Latest Developments
List of Figures
Figure 1. Picture of Carcinoid Tumor Syndrome Treatment
Figure 2. Carcinoid Tumor Syndrome Treatment Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Carcinoid Tumor Syndrome Treatment Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Carcinoid Tumor Syndrome Treatment Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Carcinoid Tumor Syndrome Treatment Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Chemotherapy
Figure 10. Product Picture of Biological Therapy
Figure 11. Product Picture of Radio Therapy
Figure 12. Global Carcinoid Tumor Syndrome Treatment Sales Market Share by Type in 2022
Figure 13. Global Carcinoid Tumor Syndrome Treatment Revenue Market Share by Type (2018-2023)
Figure 14. Carcinoid Tumor Syndrome Treatment Consumed in Hospital
Figure 15. Global Carcinoid Tumor Syndrome Treatment Market: Hospital (2018-2023) & (K Units)
Figure 16. Carcinoid Tumor Syndrome Treatment Consumed in Clinic
Figure 17. Global Carcinoid Tumor Syndrome Treatment Market: Clinic (2018-2023) & (K Units)
Figure 18. Carcinoid Tumor Syndrome Treatment Consumed in Home
Figure 19. Global Carcinoid Tumor Syndrome Treatment Market: Home (2018-2023) & (K Units)
Figure 20. Global Carcinoid Tumor Syndrome Treatment Sales Market Share by Application (2022)
Figure 21. Global Carcinoid Tumor Syndrome Treatment Revenue Market Share by Application in 2022
Figure 22. Carcinoid Tumor Syndrome Treatment Sales Market by Company in 2022 (K Units)
Figure 23. Global Carcinoid Tumor Syndrome Treatment Sales Market Share by Company in 2022
Figure 24. Carcinoid Tumor Syndrome Treatment Revenue Market by Company in 2022 ($ Million)
Figure 25. Global Carcinoid Tumor Syndrome Treatment Revenue Market Share by Company in 2022
Figure 26. Global Carcinoid Tumor Syndrome Treatment Sales Market Share by Geographic Region (2018-2023)
Figure 27. Global Carcinoid Tumor Syndrome Treatment Revenue Market Share by Geographic Region in 2022
Figure 28. Americas Carcinoid Tumor Syndrome Treatment Sales 2018-2023 (K Units)
Figure 29. Americas Carcinoid Tumor Syndrome Treatment Revenue 2018-2023 ($ Millions)
Figure 30. APAC Carcinoid Tumor Syndrome Treatment Sales 2018-2023 (K Units)
Figure 31. APAC Carcinoid Tumor Syndrome Treatment Revenue 2018-2023 ($ Millions)
Figure 32. Europe Carcinoid Tumor Syndrome Treatment Sales 2018-2023 (K Units)
Figure 33. Europe Carcinoid Tumor Syndrome Treatment Revenue 2018-2023 ($ Millions)
Figure 34. Middle East & Africa Carcinoid Tumor Syndrome Treatment Sales 2018-2023 (K Units)
Figure 35. Middle East & Africa Carcinoid Tumor Syndrome Treatment Revenue 2018-2023 ($ Millions)
Figure 36. Americas Carcinoid Tumor Syndrome Treatment Sales Market Share by Country in 2022
Figure 37. Americas Carcinoid Tumor Syndrome Treatment Revenue Market Share by Country in 2022
Figure 38. Americas Carcinoid Tumor Syndrome Treatment Sales Market Share by Type (2018-2023)
Figure 39. Americas Carcinoid Tumor Syndrome Treatment Sales Market Share by Application (2018-2023)
Figure 40. United States Carcinoid Tumor Syndrome Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 41. Canada Carcinoid Tumor Syndrome Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 42. Mexico Carcinoid Tumor Syndrome Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 43. Brazil Carcinoid Tumor Syndrome Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 44. APAC Carcinoid Tumor Syndrome Treatment Sales Market Share by Region in 2022
Figure 45. APAC Carcinoid Tumor Syndrome Treatment Revenue Market Share by Regions in 2022
Figure 46. APAC Carcinoid Tumor Syndrome Treatment Sales Market Share by Type (2018-2023)
Figure 47. APAC Carcinoid Tumor Syndrome Treatment Sales Market Share by Application (2018-2023)
Figure 48. China Carcinoid Tumor Syndrome Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 49. Japan Carcinoid Tumor Syndrome Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 50. South Korea Carcinoid Tumor Syndrome Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 51. Southeast Asia Carcinoid Tumor Syndrome Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 52. India Carcinoid Tumor Syndrome Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 53. Australia Carcinoid Tumor Syndrome Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 54. China Taiwan Carcinoid Tumor Syndrome Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 55. Europe Carcinoid Tumor Syndrome Treatment Sales Market Share by Country in 2022
Figure 56. Europe Carcinoid Tumor Syndrome Treatment Revenue Market Share by Country in 2022
Figure 57. Europe Carcinoid Tumor Syndrome Treatment Sales Market Share by Type (2018-2023)
Figure 58. Europe Carcinoid Tumor Syndrome Treatment Sales Market Share by Application (2018-2023)
Figure 59. Germany Carcinoid Tumor Syndrome Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 60. France Carcinoid Tumor Syndrome Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 61. UK Carcinoid Tumor Syndrome Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 62. Italy Carcinoid Tumor Syndrome Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 63. Russia Carcinoid Tumor Syndrome Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 64. Middle East & Africa Carcinoid Tumor Syndrome Treatment Sales Market Share by Country in 2022
Figure 65. Middle East & Africa Carcinoid Tumor Syndrome Treatment Revenue Market Share by Country in 2022
Figure 66. Middle East & Africa Carcinoid Tumor Syndrome Treatment Sales Market Share by Type (2018-2023)
Figure 67. Middle East & Africa Carcinoid Tumor Syndrome Treatment Sales Market Share by Application (2018-2023)
Figure 68. Egypt Carcinoid Tumor Syndrome Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 69. South Africa Carcinoid Tumor Syndrome Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 70. Israel Carcinoid Tumor Syndrome Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 71. Turkey Carcinoid Tumor Syndrome Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 72. GCC Country Carcinoid Tumor Syndrome Treatment Revenue Growth 2018-2023 ($ Millions)
Figure 73. Manufacturing Cost Structure Analysis of Carcinoid Tumor Syndrome Treatment in 2022
Figure 74. Manufacturing Process Analysis of Carcinoid Tumor Syndrome Treatment
Figure 75. Industry Chain Structure of Carcinoid Tumor Syndrome Treatment
Figure 76. Channels of Distribution
Figure 77. Global Carcinoid Tumor Syndrome Treatment Sales Market Forecast by Region (2024-2029)
Figure 78. Global Carcinoid Tumor Syndrome Treatment Revenue Market Share Forecast by Region (2024-2029)
Figure 79. Global Carcinoid Tumor Syndrome Treatment Sales Market Share Forecast by Type (2024-2029)
Figure 80. Global Carcinoid Tumor Syndrome Treatment Revenue Market Share Forecast by Type (2024-2029)
Figure 81. Global Carcinoid Tumor Syndrome Treatment Sales Market Share Forecast by Application (2024-2029)
Figure 82. Global Carcinoid Tumor Syndrome Treatment Revenue Market Share Forecast by Application (2024-2029)

※参考情報 カルチノイド腫瘍症候群は、一般的には内分泌腫瘍の一種であるカルチノイド腫瘍に起因する一連の症状を指します。これらの腫瘍は主に消化管（特に小腸）や肺に発生します。カルチノイド腫瘍は神経内分泌腫瘍として分類され、その多くは良性ですが、時には悪性となることがあります。この腫瘍が分泌するホルモンやその他の生理活性物質が、さまざまな症状を引き起こすことがカルチノイド腫瘍症候群の特徴です。 カルチノイド腫瘍症候群の主な症状には、潮紅、下痢、腹痛、喘鳴、心不全（特に右心房肥大や肺動脈狭窄に関連する心疾患）があります。潮紅は顔や首が紅潮する現象で、ホルモンの中でも特にセロトニンが関与しているとされています。下痢は、セロトニンが腸管運動を促進することにより引き起こされます。これらの症状は、腫瘍が進行するにつれて悪化することが一般的です。 カルチノイド腫瘍は、数種類のホルモンを分泌しますが、セロトニンが最もよく知られています。他にも、ヒスタミン、プロスタグランジン、カルシトニンなども分泌され、これらが異なる症状を引き起こすことがあります。腫瘍の場所や大きさ、または転移の有無によっても症状は異なります。 カルチノイド腫瘍症候群の診断には、様々な検査が用いられます。生化学的・腫瘍マーカー検査として、血中の5-HIAA（5-hydroxyindoleacetic acid）やセロトニン濃度の測定が行われます。5-HIAAは、セロトニンの代謝産物であり、腫瘍の存在が疑われる場合に重要な指標です。また、画像診断にはCTスキャンやMRIが用いられ、腫瘍の位置や広がりを評価します。 カルチノイド腫瘍症候群の治療には、手術、放射線療法、抗がん剤、分子標的治療、ホルモン療法などが選択肢となります。治療の選択は、腫瘍の大きさ、部位、悪性度、患者の全身状態などに基づいて決定されます。 手術は、腫瘍を完全に切除できる場合に最も効果的な治療法です。特に、腫瘍の大きさや転移の有無が重要であり、早期に発見し積極的に手術することで、予後を大きく改善することができます。しかし、腫瘍が広範囲に転移している場合には、外科的切除は難しいことがあります。 放射線療法は主に転移性のカルチノイド腫瘍に対して行われます。特に、骨または肝臓への転移があるのであれば、放射線治療が有効な場合があります。これにより、症状の緩和や腫瘍のサイズ縮小が期待されます。 抗がん剤治療は、特に標準的な手術や放射線治療が困難な場合や全身転移がある患者に対して行われることが一般的です。カルチノイド腫瘍はその性質上、抗がん剤に対する感受性が低い場合がありますが、最近は生物学的療法や分子標的治療薬が開発され、治療の選択肢が広がっています。 ホルモン療法に関しては、オクトレオチド（サンドスタチン）やランレオチドが代表的な薬剤として用いられ、腫瘍からのホルモンの分泌を抑制し、症状の緩和を目的とします。これにより、潮紅や下痢といった症状が緩和され、生活の質を向上させることができるとされています。 カルチノイド腫瘍症候群の研究は進行中であり、今後も新しい治療法の開発が期待されています。特に、遺伝子治療や免疫療法の分野は、新たな治療の可能性を秘めています。患者のニーズに応じて、治療法は進化し続けることでしょう。 さらに、カルチノイド腫瘍に関連する技術や管理方法も進化しています。診断技術の向上や、新しい検査法の開発により、腫瘍を早期に発見し、適切な治療を行うことが可能になっています。また、対症療法としてのサポーティブケアも重要であり、カルチノイド腫瘍症候群の患者に対する緩和医療の充実が求められています。 カルチノイド腫瘍症候群は、患者にとって非常に特異で、時には困難な病状。しかし、各種治療法や新しい研究の進展により、患者がより良い生活を送るための道が開かれつつあります。医療従事者は、患者一人ひとりの症状や状況に応じた柔軟なアプローチをもって治療にあたることが重要です。今後の研究と医療の進展に期待が寄せられています。

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer